Skip to main content

Ocular Therapeutix, Inc (OCUL)

Sector
Pharmaceuticals
Last price
$6.02
As of

Kresmion compiles this page from OCUL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

OCULAR THERAPEUTIX, INC (OCUL): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-09.

As of . Source: SEC EDGAR filings for OCUL. Method and limitations.

COMPANY DOSSIER

See the full OCUL dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for OCUL on one page. Preview it with sample data, then open it live with a free account.

Preview the OCUL dossier

Active events for OCUL

FREE, NO ACCOUNT

Every event on OCUL, as it fires

You are seeing 5 of 12 events recorded on OCUL since 2026-06-03.

The five above landed across 2 days. The other 7 were recorded on 2 other days. 8 of the 12 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

OCUL positions held by the managers we follow (2026Q3)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 67576A100 · 2026Q3$4.1M0.01%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, OCUL

More data on OCUL

OCUL against its peers

OCUL's operating margin of -519.8% ranks in the 13th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.

MetricOCULPeer medianPercentilen
Revenue FY52.0M USD451M USD1819
Gross margin87.3%66.3%8610
Operating margin-519.8%5.6%1318
Net margin-511.9%0.5%1319
Return on equity-40.6%-6.5%3722
P / En/a14.8xn/a9
1 year-50.2%9.9%224

Peers (25): INVA, NKTR, GPCR, PAHC, AMPH, PCRX, NUVB, OMER, ANIP, SUPN, ANRO, TRVI, HRMY, ESPR.D, COLL, ALMS, ACRS, XERS, BHC, OGN, TARS, AMLX, AVIR, LQDA, ACB. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (OCUL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in OCUL on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on OCUL in the last 180 days.

Upstream: SEC EDGAR filings for OCUL

Kresmion, "OCULAR THERAPEUTIX, INC (OCUL) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/OCUL. Upstream data: SEC EDGAR filings for OCUL.

Link to this data (HTML):

<a href="https://kresmion.com/research/OCUL">OCULAR THERAPEUTIX, INC (OCUL) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow OCUL on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to OCUL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the OCUL dossier
Share

The OCUL intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.